REVIEW

Recent advances in understanding circular RNAs [version 1; peer review: 3 approved]

Constanze Ebermann*, Theodor Schnarr*, Sabine Müller

Institute for Biochemistry, University Greifswald, Greifswald, Germany

* Equal contributors

Abstract
Exonic circular RNAs (circRNAs) have been discovered in all kingdoms of life. In many cases, the details of circRNA function and their involvement in cellular processes and diseases are not yet fully understood. However, the past few years have seen significant developments in bioinformatics and in experimental protocols that advance the ongoing research in this still-emerging field. Sophisticated methods for circRNA generation in vitro and in vivo have been developed, allowing model studies into circRNA function and application. We here review the ongoing circRNA research, giving special attention to recent progress in the field.

Keywords
Biogenesis, cancer, circRNA, disease, splicing

Open Peer Review

Invited Reviewers

| Invited Reviewers | 1 | 2 | 3 |
|-------------------|---|---|---|
| version 1         | ✓ | ✓ | ✓ |
| 29 Jun 2020       |   |   |   |

Faculty Reviews are written by members of the prestigious Faculty Opinions Faculty. They are commissioned and are peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1 Ling-Ling Chen, Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China

2 Jeremy E. Wilusz, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA

3 Amaresh C. Panda, Institute of Life Sciences, Bhubaneswar, India

Any comments on the article can be found at the end of the article.
Corresponding author: Sabine Müller (sabine.mueller@uni-greifswald.de)

Author roles: Ebermann C: Data Curation, Formal Analysis, Investigation, Methodology, Writing – Original Draft Preparation; Schnarr T: Data Curation, Formal Analysis, Investigation, Methodology, Writing – Original Draft Preparation; Müller S: Conceptualization, Data Curation, Methodology, Project Administration, Resources, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2020 Ebermann C et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Ebermann C, Schnarr T and Müller S. Recent advances in understanding circular RNAs [version 1; peer review: 3 approved] F1000Research 2020, 9(F1000 Faculty Rev):655 https://doi.org/10.12688/f1000research.25060.1

First published: 29 Jun 2020, 9(F1000 Faculty Rev):655 https://doi.org/10.12688/f1000research.25060.1
**Introduction**

Exonic circular RNAs (circRNAs) constitute a large class of regulatory non-coding endogenous RNAs with variable composition. Over the past few years, research into their biogenesis and biological function has exploded. First discovered in viroids, where they appear as circular genomes\(^1\), circRNAs have been shown to exist in all kingdoms of life, with thousands of circRNAs identified across species from archaea to humans\(^2,3\). For decades, circRNAs were considered to be extremely rare in nature and, in particular in eukaryotes, they were seen as minor RNA structural variants attributed to transcriptional noise\(^4\). Owing to progress in analytical techniques and the development of specific methodologies for the discovery and identification of circRNAs (recently reviewed in \(^5\)), this picture has dramatically changed over the past several years. It became obvious that circRNAs are abundant, evolutionarily conserved, and stable species in all eukaryotes studied today, although some eukaryotes like *Saccharomyces cerevisiae* have only very few circRNAs because of their few multi-intronic genes. The biogenesis and full functional repertoire of circRNAs have not yet been fully elucidated. Here we will review recent progress in circRNA research, focussing on new data regarding their biogenesis, cellular function, and involvement in diseases. We will extend our view to strategies for controlled generation of circRNAs *in vivo* and *in vitro* and discuss putative applications. We do not include the development of tools and biochemical methods for the accurate identification and characterization of circRNAs, since this, as mentioned above, has been extensively reviewed very recently\(^5\).

**Biogenesis of circRNAs**

Most circRNAs are expressed from known protein-coding genes and are composed of single or multiple exons\(^1\). They are produced by backsplicing, a process that occurs in a reversed orientation as compared with canonical splicing. Hence, instead of joining an upstream 5’-splice site with a downstream 3’-splice site in a sequential order to produce a linear RNA, a downstream 5’-splice site is linked to an upstream 3’-splice site to yield a circRNA (Figure 1a)\(^6,7,8\). Still, the formation of circRNA was shown to be dependent on the canonical splicing machinery, making...

---

![Figure 1. Biogenesis of circRNAs.](image)

(a) Modes of circRNA formation. (b) Factors supporting backsplicing: inverted repeat sequences (I), binding sites for RBPs of RNP (II), IRE distance (III), and m\(^6\)A-enriched sites (IV). For further explanation, see main text. ciRNA, circular RNA containing sequences from introns; ciRNA, circular RNA; IECiRNA, circular RNA containing sequences from exons with introns retained between the exons; IRE, inverted repeat; RBP, RNA-binding protein; snRNP, small nuclear ribonucleoprotein.
backsplicing a process that competes with canonical splicing\textsuperscript{10,11}. In addition to exonic circRNAs, circular RNAs containing sequences from introns (ciRNA) and circRNAs containing sequences from exons with introns retained between the exons (exon-intron circRNA or short 1EcirRNA) have been found. ciRNAs presumably result from intron lariats that escaped de-branching during canonical splicing and do not belong to circRNAs. They reside in the nucleus, where they may control the transcription of their parental genes\textsuperscript{12,13}. However, previous work also suggests that some ciRNAs are stable in the cytoplasm\textsuperscript{14,15}. Exonic circRNAs localize to the cytoplasm, where they are exported from the nucleus in a length-dependent manner\textsuperscript{16}. In general, all exons found in linear transcripts may appear in circRNAs. However, it is also possible that circRNAs contain exons which do not appear in linearly spliced transcripts\textsuperscript{17}.

Successful backsplicing requires the splice sites to be brought into proximity (Figure 1b). This often is supported by inverted repeats (IRE), especially Alu elements, flanking the exons to be circularized and allowing multiple cirRNAs to be produced from a single gene\textsuperscript{18,19}. In addition to IRE, interaction of the precursor mRNA with ribonucleoproteins (RNPs) or proteins was found to support circRNA formation\textsuperscript{12,20-22}. Other RNA-binding proteins (RBPs) that support circularization are, for example, the heterogeneous nuclear RNP L (HNRNPL)\textsuperscript{23}, double-stranded RNA-binding domain containing immune factors NF90/NF110\textsuperscript{24}, or DHX9, an abundant nuclear RNA helicase\textsuperscript{25}. Moreover, circRNA biogenesis underlies the combinatorial control of splice factors\textsuperscript{26} and can also be suppressed by helicases\textsuperscript{27}. Pre-mRNA structure plays an important role, as flanking sequences (e.g. IRE or RNP-binding sites) or the distance between splice sites is most important\textsuperscript{28}. Furthermore, N6-methylation of adenosine can promote circRNA biogenesis, as it was recently shown that m^A-enriched sites guide backsplicing in male germ cells\textsuperscript{29}. CircRNA levels are also modulated by the levels of core spliceosome components\textsuperscript{30}, and it was suggested that the same spliceosome can assemble across an exon and that it either remodels to span an intron for canonical linear splicing or catalyses backsplicing to generate circRNA\textsuperscript{31}.

Backsplicing is less efficient than linear splicing\textsuperscript{32}, and, typically, cirRNAs are produced at a lower level than their linear counterparts. Yet cirRNAs may be the more abundant isoform in specific cells and tissues\textsuperscript{33,34}, which may be attributed to their higher stability. Owing to the covalently closed ring structure, cirRNAs are resistant to degradation by exonucleases, thus undergoing slower turnover. The higher stability implies that possible functions of cirRNA may be associated with their longer lifespan. Nevertheless, there is evidence of circRNA turnover, as it was shown that upon poly(I:C) stimulation or viral infection, cirRNAs are globally degraded by RNase L, a process required for PKR activation in early cellular innate immune responses\textsuperscript{35}. Furthermore, m^A-containing cirRNAs, when bound to the m^A reader protein YTHDF2, become rapidly degraded by the RNase P/MRP complex\textsuperscript{36}. circRNA degradation is also mediated via a structure-related RNA decay pathway that is independent of specific single-stranded sequences but recognizes double-stranded structures in the 3’ UTR of mRNAs, as well as highly structured cirRNAs\textsuperscript{37}.

Biological functions of cirRNAs

To date, biological function has been investigated for only a minor fraction of cirRNAs. Many of those have been proposed to act as miRNA sponges\textsuperscript{38-42} or protein sponges\textsuperscript{43,44}. In addition, cirRNAs may enhance protein function\textsuperscript{45-47}, assist protein target interaction\textsuperscript{48-50}, or recruit proteins to specific locations\textsuperscript{51}. An early example for a potential miRNA sponge is cirRNA cirs-7, also known as CDR1as, comprising over 70 binding sites for miR-7\textsuperscript{52}. However, this function is still controversially discussed, in particular when looking at stoichiometric ratios of the target sequences to the number of binding sites in the cirRNA\textsuperscript{53,54}. Furthermore, analysis of 7,000 human cirRNAs revealed that most of them are not enriched in miRNA-binding sites\textsuperscript{3}.

Some cirRNAs possess binding sites for specific proteins, which upon binding lose interaction with other targets\textsuperscript{55}. In a similar manner, cirRNAs have been described to function as protein scaffolds, assisting the assembly of protein complexes\textsuperscript{56,57}. For example, circFoxo3 was shown to inhibit the progression of the cell cycle by formation of a ternary complex with CDK2 and p21, thereby acting as a tumor suppressor\textsuperscript{58}, or to specifically recruit the ubiquitinylation system, thus triggering degradation of mutated p53 by the proteasome complex\textsuperscript{59}. CirRNA can also regulate the subcellular localization of specific proteins, as shown for circ-Amotl1 binding to Stat3, AKT1, and PKD\textsuperscript{14,15,60,61}. Because backsplicing competes with canonical splicing, the formation of cirRNAs is also considered to be a mode of regulating the expression of a specific gene. The protein Muscleblind (MBL) binds to the flanking introns of circMBL derived from the muscleblind gene by backsplicing. As a result, MBL levels are modulated, which in turn strongly affects circMBL biosynthesis\textsuperscript{31}.

There has been some indication that cells can differentiate between endogenous and exogenous cirRNA. Exogenously introduced cirRNA was shown to have a stimulating effect on the immune system because it is recognized by the pattern recognition receptor retinoic acid inducible gene I (RIG-I), thereby eliciting a strong immune response. Apparently, this applies only to unmodified cirRNA because m^A-modified cirRNA was shown to inhibit innate immunity\textsuperscript{62}. Endogenous cirRNA, on the contrary, did not show such an effect. Based on this observation, it was proposed that endogenous cirRNA is recognized as self, owing to the identity of its flanking introns that led to circularization\textsuperscript{44}. More recent findings, however, are contradictory, as they suggest that unmodified exogenous cirRNA is able to bypass cellular RNA sensors and thus does not induce an immune response in RIG-I and Toll-like receptor (TLR) competent cells and in mice\textsuperscript{63}. Endogenous cirRNAs can collectively bind and suppress activation of the double-stranded RNA (dsRNA)-activated protein kinase PKR, thereby controlling innate immune responses\textsuperscript{5}. As already mentioned above, double-stranded RNA-binding domain-containing immune
transcription and phosphorylated at the 3’- or 5’ ends, indicating the role of circRNAs in antiviral immune response.

Interestingly, some circRNAs containing internal ribosome entry site (IRES) elements and AUG sites may be translated into unique peptides under specific conditions, in particular upon cellular stress, although the functional relevance of the majority of circRNA-derived peptides is not yet known. Earlier studies had suggested that circRNAs might be translated without the existence of an IRES sequence, following the so-called rolling circle translation mechanism. In more recent studies, however, translation of circRNAs was shown to be dependent on the presence of different IRESs (either viral IRES sequences or m^A^)-dependent translation. Yet it should be noted that even though several studies have reported cases of circRNA translation, others have completely failed to find evidence.

Taken together, circRNAs appear to play a regulatory role in different levels of gene expression, which also explains their association with diverse diseases, pathological conditions, and expression patterns specific for certain cell types and tissues.

**CircRNAs in diseases**

CircRNAs have been associated with the initiation and progression of several diseases, including cancer, neurodegenerative diseases, cardiovascular diseases, and diabetes, and thus have also been considered as biomarkers for disease prognostics and diagnostics and as targets or tools for disease treatment. There is also indication of circRNAs accumulating with aging. Work in the field is currently centered around screening for and identifying disease-associated circRNAs, whereas the underlying mechanisms of action remain mostly unknown. In particular, the involvement of circRNAs in cancer development and progression is obvious, as numerous circRNAs have been discovered to upregulate or downregulate gene expression in cancer tissues and promote cancer cell reproduction. Over the past two years, numerous circRNAs have been shown to affect cell proliferation, invasion, migration, and apoptosis and have been suggested to act as therapeutic targets or biomarkers for diagnosis and prognosis in various types of cancers. There have been indications of circRNAs occurring in the tumor microenvironment and in exosomes, with their role in cell-to-cell communication and spreading of pathological processes continuing to be unveiled. Recent results have shown that circRNA-loaded exosomes promote cell proliferation and invasion in colorectal and prostate cancer. It has been suggested that the effect of extracellular circRNAs can be reversed by the addition of siRNAs targeting those circRNAs, hence making it a promising therapeutic strategy.

Standing out in the majority of research of “more classical” diseases is the increasing knowledge of the roles of circRNAs in aging, where age-related changes in splicing, and thus in the level of IncRNAs and circRNAs, are discussed. Furthermore, it has been found that the expression of circRNAs can be sensitive to different types of pollution (organic, heavy metal, and others) and therefore might be used as a biomarker or prevention/treatment target for pollution-induced diseases.

**Strategies for controlled generation of circRNAs in vitro and in vivo**

Several methods for controlled generation of circRNAs based on chemical or enzymatic/ribozymatic strategies have been investigated. Circularization can be performed either in vitro or in vivo. For direct production of circRNA in cell culture, usually the sequence of interest is cloned into an artificial exon that is flanked by complementary intronic repeats. The plasmid is then transfected into cells, transcription is induced, and the cellular splicing machinery generates the desired circRNA. (Figure 2a). Alternatively, the sequence of interest can be cloned in between a permuted self-splicing intron (permuted intron exon [PIE] strategy, see below), such that circularization occurs by the inherent ribozyme activity of the intron. An expression vector comprising such self-splicing introns is also suited for circularization in vitro by linearization of the plasmid and subsequent in vitro transcription of the linearized template. The formed transcript undergoes circularization by its self-splicing activity.

Chemical ligation methods can be applied only for in vitro circularization. Linear RNA obtained from chemical synthesis or in vitro transcription and phosphorylated at the 5’- or 5’-terminus can be intramolecularly ligated with the help of condensing agents. In addition, enzymatic ligation with DNA or RNA ligases is an option (Figure 2b).

Recently, a seminal approach for circRNA production in vivo, called Tornado (twister optimized RNA for durable overexpression), was introduced. The twister ribozyme is employed in a combined approach with the cellular RtcB ligase. The ribozymes flanking the sequence to be circularized generate by cutting themselves off the 5’-terminal OH and 3’-terminal phosphate required by the cellular RtcB ligase to perform the following ligation step.

Already known for a while and newly moved into focus by recent studies is the PIE strategy, which uses a group I self-splicing intron (also a ribozyme) for the production of a circRNA either in vitro or in vivo. The two intron halves (5’- and 3’- intron) flanking the exon are arranged in a permuted manner, such that during splicing a circularized exon and two linear intron halves are formed (Figure 2d). The PIE strategy was successfully applied for RNA sequences up to five kilobases, and a PIE-produced circRNA carrying an IRES sequence was shown to be successfully translated in cells.

Another possibility to selectively circularize RNA sequences is utilizing the tRNA splicing machinery. A tRNA precursor is specifically recognized by the tRNA splicing endonuclease complex (TSEN) based on a bulge-helix-bulge (BHB) motif, then cleaved and ligated by a ligase, yielding the mature
Figure 2. Strategies for circRNA generation in vitro and in vivo. (a) Overexpression vector, (b) chemical or enzymatic ligation, (c) circularization via Tornado system, (d) permuted intron exon (PIE) strategy, (e) induction of backsplicing by Csy4, and (f) generation of circRNA using tRNA splicing mechanism. For further explanation, see main text. BHB, bulge-helix-bulge; IRES, internal ribosome entry site; TSEN, tRNA splicing endonuclease complex.

tRNA and a circularized intron (Figure 2f). A desired sequence can be introduced in such a construct between the two intron halves to become circularized upon tRNA splicing. Still another method exploiting the cell’s own splicing machinery for circularization is the system based on RNA cleavage by the CRISPR endonuclease Csy4. Csy4 recognizes a 16-nucleotide hairpin in RNA and specifically cleaves off the RNA downstream of that hairpin region. The protein is utilized for RNA circularization to cleave a site in a defined intron, thereby removing a competing downstream splice site, which otherwise would interfere with backsplicing, and thus inducing formation of the desired circRNA (Figure 2c).

Application of circRNAs

After research in the field of circRNA was dominated by their identification and studies into biogenesis and function, reports on the application of circRNAs have started to emerge more recently. Because of their stability and association with diseases, endogenous circRNAs are potential candidates as biomarkers or therapeutic targets. Likewise, exogenous circRNAs can be introduced into cells to fulfill a defined function. Several feasible concepts for the therapeutic application of circRNAs have already been discussed and to some extent successfully implemented. An obvious possibility for the application of circRNAs is the development of designed miRNA sponges. An artificial circRNA molecule comprising multiple binding sites for miRNA-122, which plays an essential role in the life cycle of the hepatitis C virus, was successfully used to inhibit the synthesis of viral proteins in the host cell. In a similar way, the activity of specific proteins in the cellular context was controlled by circularized aptamers. Moreover, circular aptamers have shown great potential as intracellularly expressed biosensors for defined metabolites.

Because some circRNAs play a role in alternative splicing and transcription, it is feasible to use them for the regulation of alternative splicing.
those processes within the cell, thereby driving gene expression in the direction of specific transcription and splicing products. In addition, circularization of RNA opens up the opportunity to apply RNA therapeutics that are administered as a linear construct until now (for example, mRNA vaccines) in a circular form, thereby significantly increasing their stability. If the circRNA additionally possesses an IRES sequence, translation of that RNA is possible, whereby therapeutic proteins may be expressed directly in target cells. Because of results suggesting that circRNAs can activate the immune system via the RIG-I pathway, it is also feasible to employ exogenous circRNA as an adjuvant in vaccines to elicit a more efficient immune response upon vaccination.  

In all of the approaches described above, it has to be taken into consideration that side effects may arise as a result of the applied circRNA. For example, expression of the desired circRNA from an overexpression vector or translation of a protein encoded by the circRNA can significantly vary dependent on the respective cell type. In some cases, the formation of linear RNA concatemers by rolling circle transcription was also observed. Those concatemers can lead to toxic effects within the cell. The function of immune activator mentioned above can also be a drawback of circRNA if the RNA is to be applied in a context wherein an immune response is not desired.

Conclusions

The occurrence of circRNAs in all kingdoms of life has been demonstrated, and it is beyond doubt that these abundant RNA species play important biological roles. The elucidation of circRNA function has included the development of methods for circRNA identification and characterization and of strategies for circRNA generation. It has become clear that circRNAs are strongly involved in diseases, although their action is enormously multifaceted. Even with all of the effort over the past decade to shed light onto this still-emerging field, the intracellular and extracellular roles of circRNAs as well as their functional role in bigger networks with other RNAs and proteins require ongoing endeavor to gain full understanding, and with that the opportunity to use circRNAs as biomarkers or therapeutic agents and targets.

Abbreviations

circRNA, circular RNA containing sequences from introns; circRNA, circular RNA; IRE, inverted repeats; IRES, internal ribosome entry site; MBL, muscleblind; PIE, permuted intron exon; RIG-I, retinoic acid inducible gene I; RNP, ribonucleoprotein.

References

1. Flores R, Grubb D, Elleuch A, et al.: Rolling-circle replication of viroids, viroid-like satellite RNAs and hepatitis delta virus: Variations on a theme. RNA Biol. 2011; 8(2): 200–6. PubMed Abstract | Publisher Full Text
2. Danan M, Schwartz S, Edelheit S, et al.: Transcriptome-wide discovery of circular RNAs in Archaea. Nucleic Acids Res. 2012; 40(7): 3131–42. PubMed Abstract | Publisher Full Text | Free Full Text
3. Guo JU, Agarwal V, Guo H, et al.: Expanded identification and characterization of mammalian circular RNAs. Genome Biol. 2014; 15(7): 409. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation
4. Cocquereille C, Mascarena B, Hétilu D, et al.: Mis-splicing yields circular RNA molecules. PASEB J 1995; 7(1): 155–60. PubMed Abstract | Publisher Full Text
5. Kristensen LS, Andersen MS, Stagsted LVW, et al.: The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019; 20(11): 675–91. PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation
6. Ivanov A, Memczak S, Wyler E, et al.: Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. Cell Rep. 2015; 10(2): 170–7. PubMed Abstract | Publisher Full Text
7. Kelly S, Greenman C, Cook PR, et al.: Exon Skipping Is Correlated with Exon Circularization. J Mol Biol. 2015; 427(15): 2414–7. PubMed Abstract | Publisher Full Text
8. Zhang XO, Wang HB, Zhang Y, et al.: Complementary sequence-mediated exon circularization. Cell. 2014; 159(1): 134–47. PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation
9. Barnett SP, Wang PL, Salzman J: Circular RNA biogenesis can proceed through an exon-containing lariat precursor. eLife. 2015; 4: e07540. PubMed Abstract | Publisher Full Text | Free Full Text
10. Sterke S, Jost I, Roobach O, et al.: Exon circularization requires canonical splice signals. Cell Rep. 2015; 10(1): 103–11. PubMed Abstract | Publisher Full Text
11. Ashwal-Fluss R, Meyer M, Parnoudri NR, et al.: circRNA Biogenesis Competes with Pre-mRNA Splicing. Mol Cell. 2014; 56(1): 55–66. PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation
12. Li Z, Huang C, Bao C, et al.: Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015; 22(3): 256–64. PubMed Abstract | Publisher Full Text
13. Zhang Y, Zhang XO, Chen T, et al.: Circular Intronic Long Noncoding RNAs. Mol Cell. 2013; 51(6): 792–806. PubMed Abstract | Publisher Full Text
14. Talhouarne GJS, Gall JG: Lariat intronic RNAs in the cytoplasm of vertebrate cells. Proc Natl Acad Sci U S A. 2018; 115(34): E7970–E7977. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation
15. Talhouarne GJS, Gall JG: Lariat intronic RNAs in the cytoplasm of Xenopus tropicalis oocytes. RNA. 2014; 20(9): 1476–87. PubMed Abstract | Publisher Full Text | Free Full Text
16. Huang C, Liang D, Tatomer DC, et al.: A length-dependent evolutionarily conserved pathway controls nuclear export of circular RNAs. Genes Dev. 2018; 32(9–10): 639–44. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation
17. Zhang XO, Dong R, Zhang Y, et al.: Diverse alternative back-splicing and alternative splicing landscape of circular RNAs. Genome Res. 2016; 26(9): 1277–87. PubMed Abstract | Publisher Full Text | Free Full Text
18. Jack WR, Sorrentino JA, Wang K, et al.: Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013; 19(2): 141–57. PubMed Abstract | Publisher Full Text | Free Full Text
19. Liang D, Wilusz JE: Short intronic repeat sequences facilitate circular RNA production. Genes Dev. 2014; 28(20): 2233–47. PubMed Abstract | Publisher Full Text | Free Full Text
20. Conn SJ, Pillman KA, Touba J, et al.: The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015; 160(5): 1125–34. PubMed Abstract | Publisher Full Text
21. Kramer MC, Liang D, Tatomer DC, et al.: Combinatorial control of Dro sophila circular RNA expression by intronic repeats, lntRNAs, and SR proteins. Genes Dev. 2015; 29(20): 2168–82. PubMed Abstract | Publisher Full Text | Free Full Text
22. Nasim FUH, Hutchison S, Cordeau M, et al.: High-affinity lntRNA A1 binding sites and duplex-forming inverted repeats have similar effects on 5’ splice site selection in support of a common looping out and repression mechanism.
RNA: 2002; 8(8): 1079-89.

23. Lamichhane R, Daubner GM, Thomas-Crusells J, et al. RNA looping by PTB: Evidence using FRET and NMR spectroscopy for a role in splicing repression. Proc Natl Acad Sci U S A. 2010; 107(4): 1405–10.

24. Fei T, Chen Y, Xiao T, et al.: Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. Proc Natl Acad Sci U S A. 2017; 114(26): E5207–E5215.

25. Li X, Liu CX, Xue W, et al.: Coordinated circRNA Biogenesis and Function with N6/4NPF110 in Viral Infection. Mol Cell. 2017; 67(2): 214–227.e7.

26. Akty T, Ayar Ilik I, Maticzka D, et al.: DHX9 suppresses RNA processing defects originating from the Ato invasion of the human genome. Nature. 2017; 544(7648): 115–9.

27. Ottesen EW, Luo D, Seo J, et al.: Human Survival Motor Neuron genes generate a vast repertoire of circular RNAs. Nucleic Acids Res. 2019; 47(6): 2886–900.

28. Welden JR, Stamm S: Pre-mRNA structures forming circular RNAs. Biochim Biophys Acta Gene Regul Mech. 2018; 1821(1-12): 134410.

29. Fang Y, Wang X, Li W, et al.: Induction of tumor apoptosis through a circular RNA enhancing Foxo activity. Cell Death Differ. 2017; 24(2): 357–70.

30. Liang D, Tatomer DC, Luo Z, et al.: The Output of Protein-Coding Genes Shifts to Circular RNAs When the Pre-mRNA Processing Machinery Is Limiting. Mol Cell. 2017; 68(5): 940–54.e3.

31. Li X, Liu S, Zhang L, et al.: A unified mechanism for intron and exon definition and back-splicing. Nature. 2019; 573(7774): 375–80.

32. Li X, Liu S, Zhang L, et al.: A unified mechanism for intron and exon definition and back-splicing. Nature. 2019; 573(7774): 375–80.

33. Zhang Y, Xue W, Li X, et al.: The Biogenesis of Nascent Circular RNAs. Cell Rep. 2016; 15(3): 611–24.

34. Salzman J, Gawad C, Wang PL, et al.: Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PloS One. 2012; 7(2): e30773.

35. Tang C, Xie Y, Yu T, et al.: m6A-dependent biogenesis of circular RNAs in male germ cells. Cell Res. 2020; 30(3): 211–28.

36. Li X, Liu S, Zhang L, et al.: A unified mechanism for intron and exon definition and back-splicing. Nature. 2019; 573(7774): 375–80.

37. Liu J, Li D, Luo H, et al.: Circular RNAs: The star molecules in cancer. Mol Aspects Med. 2019; 70: 141–52.

38. Park OH, Ha H, Lee Y, et al.: Endonucleolytic Cleavage of m6A-Containing RNAs by RNase PMRP Complex. Mol Cell. 2019; 74(3): 484–507.e8.

39. Fischer JW, Bussa VF, Shao Y, et al.: Structure-Mediated RNA Decay by UPF1 and G3BP1. Mol Cell. 2020; 78(1): 70–84.e7.

40. Przemecka M, Glazar P, Hernandez-Miranda LR, et al.: Loss of a mammalian circular RNA locus causes miRNA deregulation and affects brain function. Science. 2017; 357(6357): eaam8526.

41. Hansen TB, Jensen TI, Clausen BH, et al.: Natural RNA circles function as efficient microRNA sponges. Nature. 2013; 495(7441): 384–8.

42. Hanszen TB, Jensen TI, Clausen BH, et al.: Natural RNA circles function as efficient microRNA sponges. Nature. 2013; 495(7441): 384–8.

43. Mendzak S, Jens M, EieIstoni A, et al.: Circular RNAs are a large class of animal RNAs with regulatory potential. Nature. 2013; 495(7441): 333–8.

44. Haussler J, Zavolan M: Identification and consequences of miRNA-target interactions—beyond repression of gene expression. Nat Rev Genet. 2014; 15(9): 599–612.

45. Abdelmohsen K, Panda AC, Munk R, et al.: Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by CircPABPN1. RNA Biol. 2017; 14(3): 361–9.
as a rising interest in laboratory medicine. Clin Chem Lab Med. 2018; 56(12): 1992–2003. PubMed Abstract | Publisher Full Text

112. Holdt LM, Kohlmaier A, Teupser D: Circular RNAs as Therapeutic Agents and Targets. Front Physiol. 2018; 9: 1262. PubMed Abstract | Publisher Full Text | Free Full Text

113. Li Z, Ruan Y, Zhang H, et al.: Tumor-suppressive circular RNAs: Mechanisms underlying their suppression of tumor occurrence and use as therapeutic targets. Cancer Sci. 2019; 110(12): 3630–8. PubMed Abstract | Publisher Full Text | Free Full Text

114. Jost I, Shalamova LA, Gerresheim GK, et al.: Functional sequestration of microRNA-122 from Hepatitis C Virus by circular RNA sponges. RNA Biol. 2018; 15(8): 1032–9. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

115. Meganck RM, Borchardt EK, Castellanos Rivera RM, et al.: Tissue-Dependent Expression and Translation of Circular RNAs with Recombinant AAV Vectors In Vivo. Mol Ther Nucleic Acids. 2018; 13: 89–98. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation
Open Peer Review

Current Peer Review Status: ✔️ ✔️ ✔️

Editorial Note on the Review Process
Faculty Reviews are written by members of the prestigious Faculty Opinions Faculty. They are commissioned and are peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. Amaresh C. Panda
   Institute of Life Sciences, Bhubaneswar, India
   **Competing Interests:** No competing interests were disclosed.

2. Jeremy E. Wilusz
   Department of Biochemistry and Biophysics, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA
   **Competing Interests:** No competing interests were disclosed.

3. Ling-Ling Chen
   State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China
   **Competing Interests:** No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com